Acute Whey Protein And Casein Supplementation: Effect On Protein Metabolism After Resistance Exercise

Overview

The proteins of human breast milk are the most important endocrine signaling system that promotes neonatal growth by increasing the release of insulin, insulin-like growth factor-1 (IGF-1), and the leucine-mediated mammalian target of rapamycin complex 1- (mTORC1) signaling of pancreatic β-cells. Remarkably, the branched-chain amino acids (BCAAs) leucine, isoleucine, and valine are involved in the growth-promoting effects of milk, protein biosynthesis, and metabolism because they physiologically stimulate insulin secretion The present study sought to investigate the effects of the combination of whey protein and casein in the ratio of 80:20 ("whey protein: casein" or "casein: whey protein") as breast milk proportion on the peak and the period of the permanence of branched-chain amino acids in the blood circulation, final metabolites of protein metabolism and delayed onset muscle soreness (DOMS) after a single bout of fasting or a resistance exercise session.

Full Title of Study: “Association of Whey Protein and Casein in the Same Proportions of Human Breast Milk Promoted Similar Branched-chain Amino Acids Profile and Reduced Delayed Muscle Soreness in Physically Active Man”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Basic Science
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: July 20, 2019

Detailed Description

The present study investigated the effects of the association of WP and casein in the ratio of 80:20, a similar ratio of human breast milk, on blood branched-chain amino acids (BCAAs) profile by HPLC technique, markers of protein metabolism (creatinine, urea, and urine nitrogen) and delayed onset muscle soreness (DOMS) after a single bout of resistance exercise. A double-blind, crossover and acute study was conducted with ten men (age 29 ± 8 y; BMI: 25.4 ± 2.9 Kg/m2; 77 ± 12 kg; 1.74 ± 0.09 m) that were randomly assigned to five supplementation treatments: WP – whey protein; CAS – casein; WP/CAS – 80% WP/20% CAS; CAS/WP – 80% CAS/ 20% WP; PLA – placebo. Participants were submitted to the following evaluations: performance sessions, blood collection for each session for the BCAAs profile determination, two food records, 3-days assessment of DOMS (24h, 48h, 72h) after each treatment.

Interventions

  • Dietary Supplement: Blend Protein Supplementation
    • Protein supplementation using 20 grams of whey protein or casein mix. Acute Resistance training, 10 sets of 10 reps at 85% of 1Maximum repetition
  • Dietary Supplement: Placebo Supplementation
    • Placebo supplementation using 20 grams of Maltodextrin. Acute Resistance training, 10 sets of 10 reps at 85% of 1Maximum repetition
  • Other: Resistance Exercise
    • 10 sets of 10 repetitions at 85% of 1 Maximum repetition in leg press exercise

Arms, Groups and Cohorts

  • Experimental: Protein Supplementation and Resistance exercise
    • Protein supplementation composed of 20 gram of whey protein or casein in different proportions (80:20) and fasting state 10 sets of 10 reps at 85% of 1 Maximum repetition
  • Placebo Comparator: Placebo Supplementation
    • Placebo supplementation composed of 20 gram of Maltodextrin and fasting state 10 sets of 10 reps at 85% of 1 Maximum repetition
  • Experimental: Resistance Training
    • Resistance Exercise will be performed before supplementation and is composed by 10 sets of 10 repetitions at 85% of 1 Maximum repetition in leg press exercise.

Clinical Trial Outcome Measures

Primary Measures

  • Change from baseline in plasma amino acids concentration
    • Time Frame: 5 weeks
    • Blood sample collected for analysis of BCAA concentration after blend protein or placebo supplementation expressed in (µmol/L)
  • Change from baseline in 1RM test
    • Time Frame: 5 weeks
    • Change of training load using RPE, time and load expressed in (a.u)
  • Change in protein metabolism
    • Time Frame: 5 weeks
    • Change in nitrogen excretion, and nitrogen balance after protein supplementation expressed in (g/24 hours)
  • Changes from baseline in macronutrient intake
    • Time Frame: 5 weeks
    • Change of macronutrient intake were calculated pre and post treatment expressed in (g/24 hours)
  • Change in delayed onset muscle soreness
    • Time Frame: 5 weeks
    • Change from baseline the delayed onset muscle soreness pre, post, 24 hours, 48 hours and 72 hours after treatment expressed in (a.u)

Participating in This Clinical Trial

Inclusion Criteria

  • Healthy – practice resistance training at least 3x a week Exclusion Criteria:

  • Smokers – Muscle injures – cardiovascular diseases – Diabetes mellitus – Lactose intolerance

Gender Eligibility: Male

Minimum Age: 20 Years

Maximum Age: 40 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Sao Paulo
  • Collaborator
    • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • Provider of Information About this Clinical Study
    • Principal Investigator: Ellen Cristini de Freitas, Principal Investigator – University of Sao Paulo

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.